Business Description
Nektar Therapeutics
ISIN : US6402683063
Total Employee Number:
63Compare
Compare
Traded in other countries / regions
NKTR.USA0UNL.UKITH0.GermanyNKTR.Mexico IPO Date
2026-06-04Description
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 8.71 | |||||
Equity-to-Asset | 0.83 | |||||
Debt-to-Equity | 0.09 | |||||
Debt-to-EBITDA | -0.65 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 3.4 | |||||
Beneish M-Score | 3.57 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -23.7 | |||||
3-Year EBITDA Growth Rate | 33.5 | |||||
3-Year EPS without NRI Growth Rate | 26.4 | |||||
3-Year FCF Growth Rate | 20.7 | |||||
3-Year Book Growth Rate | -46.7 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -14.11 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 56.57 | |||||
9-Day RSI | 55.54 | |||||
14-Day RSI | 57.4 | |||||
3-1 Month Momentum % | 836.26 | |||||
6-1 Month Momentum % | 836.26 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 10.42 | |||||
Quick Ratio | 10.42 | |||||
Cash Ratio | 9.64 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -17.5 | |||||
Shareholder Yield % | -34.56 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -239.32 | |||||
Net Margin % | -287.84 | |||||
EBITDA Margin % | -222.49 | |||||
FCF Margin % | -428.72 | |||||
OCF Margin % | -428.27 | |||||
ROE % | -48.2 | |||||
ROA % | -29.67 | |||||
ROIC % | -90.08 | |||||
3-Year ROIIC % | -70.56 | |||||
ROC (Joel Greenblatt) % | -1533.78 | |||||
ROCE % | -26.24 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 30.35 | |||||
PB Ratio | 2.8 | |||||
Price-to-Tangible-Book | 2.8 | |||||
EV-to-EBIT | -15.73 | |||||
EV-to-EBITDA | -15.82 | |||||
EV-to-Revenue | 35.2 | |||||
EV-to-Forward-Revenue | 46.3 | |||||
EV-to-FCF | -8.21 | |||||
Price-to-GF-Value | 12.88 | |||||
Price-to-Median-PS-Value | 2.77 | |||||
| Price-to-Net-Current-Asset-Value | 4.61 | |||||
| Price-to-Net-Cash | 5.13 | |||||
Earnings Yield (Greenblatt) % | -6.36 | |||||
FCF Yield % | -9.26 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nektar Therapeutics Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 54.589 | ||
| EPS (TTM) (€) | - | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 57.4 | ||
| 14-Day ATR (€) | 1.520265 | ||
| 20-Day SMA (€) | 63.011 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 6.15 - 66.72 | ||
| Shares Outstanding (Mil) |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nektar Therapeutics Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nektar Therapeutics Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 17:00 | In 76 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 75 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-13 17:00 | 66.20 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-08-13 | 66.20 (+0.00%) | ||
| General meeting for 2026 | 2026-06-04 14:00 | 6.15 (+0.00%) | ||
| Guidance call for 2026 | 2026-06-03 13:20 | 6.15 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 17:00 | 6.15 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 6.15 (+0.00%) | ||
| Analyst and Investor Event with Alopecia Areata Experts | 2026-04-20 08:00 | 6.15 (+0.00%) | ||
| Annual report for 2025 | 2026-03-13 | 6.15 (+0.00%) |
Show
Entries
Nektar Therapeutics Frequently Asked Questions
What is Nektar Therapeutics(XTER:ITH0)'s stock price today?
The current price of XTER:ITH0 is €64.28. The 52 week high of XTER:ITH0 is €66.72 and 52 week low is €6.15.
When is next earnings date of Nektar Therapeutics(XTER:ITH0)?
The next earnings date of Nektar Therapeutics(XTER:ITH0) is 2026-11-06 Est..
Does Nektar Therapeutics(XTER:ITH0) pay dividends? If so, how much?
Nektar Therapeutics(XTER:ITH0) does not pay dividend.
Press Release
Articles on Nektar Therapeutics
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers